Summit Therapeutics Inc. SMMT
- Headquarters
- Miami, FL
- Next results
- around Jan 11, 2027
What changed
24 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 23, 2026 against Feb 24, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Critical audit matters changedNew this year: External Research and Development Costs (“The Company’s research and development expense for the year ended December 31, 2025 was $537.7 million, of which a portion relates to external research and development costs. As described in Note 2 to the consolidated financial statements, research and development costs are expensed as incurred. Res”). No longer listed: Research and Development Prepaid Expenses and Accrued Liabilities
-
Cash from operations −$322.9M vs net income −$1.1B (FY ending Dec 31, 2025)
7 more checks with nothing to note
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
24 paragraphs in Risk Factors that were not in the 10-K filed Feb 24, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
In January 2026, the FDA accepted for filing our BLA seeking approval of ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-TKI therapy and provided a PDUFA target action date of November 14, 2026. The delay or denial of regulatory approval, inability to…
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We have conducted, and may in the future conduct, clinical trials for current or future product candidates…
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
Evolving competition with new products or existing products with new data or combinations which may confer efficacy or safety advantages.
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
The manufacturing process for a product candidate is subject to FDA and other foreign regulatory authority review. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Revenue | $1.8M | $705K | $0 | $0 |
| Net income | −$88.6M | −$78.8M | −$614.9M | −$221.3M |
| Operating cash flow | −$72.6M | −$41.6M | −$76.8M | −$142.1M |
| Free cash flow | −$72.9M | −$42.2M | −$76.9M | −$142.2M |
Revenue, FY2019 to FY2024
Ten fiscal years, each from its own 10-K · XBRL · USD
$0 in FY2024−$221.3M in FY2024−$142.2M in FY2024
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
8-KNov 4, 2026Quarterly results, Bylaws or fiscal year changed, Shareholder vote results 8-K items 2.02, 5.03, 5.07
-
8-KNov 4, 2026Other events 8-K item 8.01
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Summit Therapeutics Inc., Miami, FL · from the 10-K filed Feb 23, 2026
Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company’s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.
- Headquarters
- Miami, FL
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
Email alerts
Sources
The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 24, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SMMT/export.csv") into a cell.